Tarlatamab (Imdelltra) is a new type of immunotherapy approved for people with small-cell lung cancer whose disease has progressed after chemotherapy and immunotherapy.

Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

University of Queensland researchers who mapped cancer cell "neighborhoods" in the most common type of lung cancer have found ...

Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...

On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...

Survival of patients with anal adenocarcinoma in comparison to rectal adenocarcinoma: A perspective from the United States National Cancer Database. Overall mortality, mean survival time, and landmark ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...